Biocon Biologics acquires Viatris’ biosimilar assets for up to US $ 3.3 billion
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
Citizens will be able to create their ABHA (Ayushman Bharat Health Account) numbers, to which their digital health records can be linked
100% efficacy against severe Covid-19 disease and hospitalizations
This new mandate builds upon and strengthens Azelis and Roquette’s global strategic partnership which spans multiple regions and industries.
Alchemee's flagship brand Proactiv@ is an iconic product synonymous with acne care
he financing was significantly oversubscribed with high demand from both existing and new investors.
Revenue of $1.67 billion represents 8% reported growth; and up 9% on a core(basis.
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
The SureSTART consumables portfolio is designed for higher performance requirements, while meeting customer budgets
US $ 555,000 invested by Wavemaker Partners in pre-seed round
Subscribe To Our Newsletter & Stay Updated